The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $9.23

Today's change-0.05 -0.54%
Updated August 31 9:58 AM EDT. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $9.23

Today's change-0.05 -0.54%
Updated August 31 9:58 AM EDT. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc down (U.S.)$0.05

Infinity Pharmaceuticals Inc is lower today, dropping (U.S.)$0.05 or 0.54% to (U.S.)$9.23. Over the last five days, shares have gained 7.95%, but are down 45.35% for the last year to date. Shares have underperformed the S&P 500 by 16.81% during the last year.

Key company metrics

  • Open(U.S.) $9.18
  • Previous close(U.S.) $9.28
  • High(U.S.) $9.36
  • Low(U.S.) $9.18
  • Bid / Ask(U.S.) $9.21 / (U.S.) $9.25
  • YTD % change-45.35%
  • Volume19,647
  • Average volume (10-day)887,811
  • Average volume (1-month)788,087
  • Average volume (3-month)667,061
  • 52-week range(U.S.) $7.56 to (U.S.) $18.25
  • Beta1.10
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.39
Updated August 31 9:58 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-39.52%

Although this company's net profit margin is negative, it is above the industry average and implies that Infinity Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX1.31%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue544161
Total other revenue--------
Total revenue544161
Gross profit--------
Total cost of revenue--------
Total operating expense43974353
Selling / general / administrative9978
Research & development34883645
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-39-93-39108
Interest income (expense), net non-operating0-1-1-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-38-93-40103
Income after tax-38-93-40103
Income tax, total----0--
Net income-38-93-40103
Total adjustments to net income-------2
Net income before extra. items-38-93-40103
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-38-93-40101
Inc. avail. to common incl. extra. items-38-93-40101
Diluted net income-38-93-40101
Dilution adjustment--------
Diluted weighted average shares49494950
Diluted EPS excluding extraordinary itemsvalue per share-0.78-1.91-0.832.03
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.78-1.91-0.832.03